skip to Main Content

Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer

Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments.

A glycolytic subtype indicates poor survival in pancreatic cancer patients, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Read more . . .


Back To Top